Comparing Genelux (NASDAQ:GNLX) and REGENXBIO (NASDAQ:RGNX)

Genelux (NASDAQ:GNLX) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Genelux and REGENXBIO, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1	0	2	1	2.75
REGENXBIO	1	3	9	1	2.71

Genelux currently has a consensus price target of $20.00, indicating a potential upside of 930.93%. REGENXBIO has a consensus price target of $23.17, indicating a potential upside of 243.46%. Given Genelux’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Genelux is more favorable than REGENXBIO.

Valuation & Earnings

This table compares Genelux and REGENXBIO”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10,000.00	8,776.56	-$32.15 million	($0.86)	-2.26
REGENXBIO	$170.44 million	2.61	-$193.88 million	($3.79)	-1.78

Genelux has higher earnings, but lower revenue than REGENXBIO. Genelux is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Genelux has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Genelux and REGENXBIO’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
REGENXBIO	-112.58%	-220.07%	-46.04%

Institutional & Insider Ownership

37.3% of Genelux shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

About REGENXBIO

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.